A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.

Pierre DuquetteMichael YeungSoukaïna MouallifHamid Reza NakhaipourPaola HaddadRobyn Schecter

Published in: PloS one (2019)

The compliance rate in fingolimod treated patients at the 24 month time point was higher than that observed in natalizumab treated patients. The discontinuation rate was lower with fingolimod compared to other DMTs at all time points but was similar to teriflunomide.

Keyphrases

multiple sclerosis
newly diagnosed
end stage renal disease
ejection fraction
prognostic factors
health insurance